Phase II Randomized Study of Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Condition:   Bladder Cancer Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Bladder Cancer;   Urothelial Carcinoma Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis. Recently, the programmed death-1 (PD-1) inhibitor pembrolizumab provided a better survival benefit with a complete response rate (9.2%) for chemoresistatant urothelial carcinoma. However, the dynamic changes of the cancer microenvironment about the cases of complete response are still unknown. We herein report a case of a 57-year-old man who had been diagnosed with localized, non-muscle-invasive bladder cancer (pT1N0M0, high grade), f...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Patients with intermediate or locally advanced rectal carcinoma are treated according to international guidelines with neoadjuvant radiotherapy with or without concurrent chemotherapy followed by total mesorectal excision surgery.[1,2] Neoadjuvant radiotherapy leads to a reduction in local recurrence rate but is still associated with substantial toxicity as large planning volumes are needed to compensate for inter- and intrafraction movement.[3,4] Particularly the mesorectum is a nonstationary structure, with large day-to-day variation as its shape and volume are affected by both bladder and rectal filling.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Conditions:   Urothelial Carcinoma;   Bladder Cancer Interventions:   Drug: Toripalimab;   Drug: Gemcitabine Sponsor:   Henan Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The objective of this study was to assess the survival of the predominant variant histologies of tumors of the renal pelvis (RPT) after surgical intervention, and to examine the influence of AC on the OS of the different variant histologies.MethodsWe identified 21,318 patients with RPT undergoing surgical intervention using the National Cancer Database for the period 2004 –2015. We employed multivariable Cox proportional hazards regression models and Kaplan–Meier curves to evaluate the OS according to variant histology. Separate multivariable Cox regression models were used to assess the specific effect of AC o...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Condition:   Muscle-Invasive Bladder Carcinoma Intervention:   Drug: AMVAC + Nivolumab Sponsor:   Fox Chase Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Neoadjuvant Therapy | Research | Study